The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial
Open accessThe DOI matches its Crossref record.
Abstract
Summary: In a phase‐II multi‐centre double‐blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5–53 years old. Subjects were randomized to HC + placebo, Mg + placebo, HC + Mg, or placebo + placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8 weeks. Thirty‐six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso‐occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Effects of hydroxyurea treatment for patients with hemoglobin SC disease
Luchtman‐Jones, L., Pressel, S., Hilliard, L., Brown, R. C., Smith, M. G., Thompson, A. A., Lee, M. T., Rothman, J., Rogers, Z. R., Owen, W., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24255 · Cited by 86
Self-citationSummarell, C. C. G., & Sheehan, V. A. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216639737 · Cited by 17
“In the CHAMPS study, %DRBC were measured by an ADVIA hematology analyzer and showed no change with hydroxyurea or magnesium pidolate therapy.(13) Patient 9 suffered a central retinal artery occlusion at the age of 12, and a branch retinal artery occlusion (BRAO) four years later.”
Chronic administration of hydroxyurea (HU) benefits caucasian patients with sickle-beta thalassemia
Di Maggio, R., Hsieh, M., Zhao, X., Calvaruso, G., Rigano, P., Renda, D., Tisdale, J., & Maggio, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030681 · Cited by 12
“The rate of HU administration, in this Caucasian cohort of patients with Sickle-Cell BetaThalassemia, was comparable with the recent papers reporting as HU rate of administration was 50% both in the inpatient cohort of a multi-center study [24] and in the US federal and state insurance-based analysis [25].”
Result
Metadata
- Authors
- Wang, W., Brugnara, C., Snyder, C., Wynn, L., Rogers, Z., Kalinyak, K., Brown, C., Qureshi, A., Bigelow, C., Neumayr, L., Smith‐Whitley, K., Chui, D. H. K., Delahunty, M., Woolson, R., Steinberg, M., Telen, M., & Kesler, K.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2011-01-31
- Volume
- 152
- Issue
- 6
- Pages
- 771-776
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1589993179
- Cited by
- 42
- References
- 0
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. https://app.cochat.ai/papers/10.1111/j.1365-2141.2010.08523.x
- The paper
- Wang, W., Brugnara, C., Snyder, C., Wynn, L., Rogers, Z., Kalinyak, K., Brown, C., Qureshi, A., Bigelow, C., Neumayr, L., Smith‐Whitley, K., Chui, D. H. K., Delahunty, M., Woolson, R., Steinberg, M., Telen, M., & Kesler, K. (2011). The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2010.08523.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.